SB-649,915

SB-649,915
Clinical data
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 6-[(1-[3-(2-methylquinolin-5-yl)oxypropyl]piperidin-4-yl)methyl]-4H-1,4-benzoxazin-3-one;
CAS Number	420785-70-2;
PubChemCID	10225553;
IUPHAR/BPS	76;
ChemSpider	8471882;
UNII	HD3UV2MFJ8;
ChEMBL	ChEMBL183460;
Chemical and physical data
Formula	C26H29N3O3
Molar mass	431.536g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4COc1ccc(cc1N4)CC(CC5)CCN5CCOc(cccc2n3)c2ccc3C;
	InChI InChI=1S/C26H29N3O3/c1-18-5-7-21-22(27-18)3-2-4-24(21)31-14-13-29-11-9-19(10-12-29)15-20-6-8-25-23(16-20)28-26(30)17-32-25/h2-8,16,19H,9-15,17H2,1H3,(H,28,30); Key:PJSUYRBCBFPCQW-UHFFFAOYSA-N;
	(what is this?)(verify)

SB-649,915is aserotonin reuptake inhibitorand5-HT_1Aand5-HT_1Breceptor antagonistwhich is being investigated for itsantidepressanteffects.^[1]Relative to theselective serotonin reuptake inhibitors(SSRIs), SB-649,915 has a fasteronset of actionand may also have greater clinical efficacy as well.^[1]This can be attributed to blockade of 5-HT_1Aand 5-HT_1Bautoreceptorswhich inhibitserotoninrelease.^[1]

References

^^a ^b ^cStarr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, Dawson LA, Hagan JJ, Upton N, Duxon MS (2007)."SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test".Neuropsychopharmacology.32(10): 2163–2172.doi:10.1038/sj.npp.1301341.PMID 17356576.

[pmid17356576-1] Starr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, Dawson LA, Hagan JJ, Upton N, Duxon MS (2007)."SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test".Neuropsychopharmacology.32(10): 2163–2172.doi:10.1038/sj.npp.1301341.PMID 17356576.

[1]

v t e Anxiolytics(N05B)
5-HT_1ARTooltip 5-HT1A receptoragonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptorPAMsTooltip positive allosteric modulators	Benzodiazepines:Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam;Others:Alpidem^‡ Barbiturates(e.g.,phenobarbital) Carbamates(e.g.,meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δVDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors(e.g.,escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors(e.g.,duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors(e.g.,trazodone) TCAsTooltip Tricyclic antidepressants(e.g.,clomipramine^#) TeCAsTooltip Tetracyclic antidepressants(e.g.,mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors(e.g.,phenelzine);Others:Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers(e.g.,prazosin) Alpha-2 agonists(e.g.,clonidine,dexmedetomidine,guanfacine) Beta blockers(e.g.,propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawnfrom market Clinical trials: ^†Phase III ^§Never to phase III

See also

References